Spravato and Ketamine Treatment

Spravato is a FDA-approved nasal spray medication designed for the treatment of depression that has not responded adequately to traditional treatment methods for depression such as oral medications and talk therapy. What sets this treatment apart is its innovative mechanism of action, Spravato is an NMDA receptor antagonist that is believed to work differently than traditional medications by acting on a pathway in the brain that affects glutamate. 

 

This medication is administered under close medical supervision in a healthcare facility. Allowing healthcare professionals to closely monitor your response and ensure your safety during treatment.

 

The administration method involves an intra-nasal spray. The standard treatment protocol typically begins with twice-weekly sessions for one month, followed by weekly sessions for the subsequent month. Any further treatment beyond this initial phase is determined on a case-by-case basis, depending on your individual progress and clinical assessment.